Development of risk prediction models for breast, ovarian and prostate cancer

Start Date Jul 2016

Code C9-Aff

Status Ongoing

Project Lead
Senior Lead
Prof Antonis Antoniou
Others
Dr Fiona Walter, Dr Marc Tischkowitz, Prof Doug Easton (all Cambridge), Prof Jon Emery (Melbourne)

Introduction

Risk stratified approaches to cancer prevention, early detection and diagnosis are of increasing interest for primary care. The CanRisk programme is exploring the use of these risk-stratified approaches to predict the likelihood of a person developing a breast, ovarian or prostate cancer, in order to start reducing risk with screening, lifestyle changes and medication.

Funding

Cancer Research UK

Aims & objectives

The main objective is to develop and validate new tools that include discoveries from both cancer genomics and epidemiology.

The CanRisk (cancer risk) assessment tool has been designed to assist clinicians in all clinical settings including primary care and genetics clinics. During a consultation, it can assist with collecting information from patients about themselves, their lifestyle, clinical, hormonal, medication and family history risk factors. This information is used to calculate a cancer risk estimate, which is linked to management recommendations (e.g. screening, preventive medication). The risk prediction is presented using a range of visual recommendations based on current best evidence from risk communication research, and according to NICE management guidelines.

Methodology

Our workstream focuses on engaging with stakeholders through workshops and mixed methods research set among primary care and clinical genetics users. We initially assessed the barriers and facilitators to implementation among each clinical group. We are now aiming to characterise the usability and usefulness of the prototypes in the various clinical settings, ultimately aiming to assess the refined version of the CanRisk tool with patients in primary care and other clinical settings.

Publications

Back to Research